Treatment with anti-EphA2 antibody significantly decreased HCMV infection of glioblastoma cells in a dose-dependent manner (Fig 4B) and showed no cytotoxicity (S6B Fig). This evidence concerns the gene EPHA2 and cytomegalovirus infection.